Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Islamic Republic of Iran; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran.
Pathol Res Pract. 2023 Sep;249:154784. doi: 10.1016/j.prp.2023.154784. Epub 2023 Aug 24.
Different cancer types have been shown to have down-regulated expression levels of miR-195 as an anti-tumor agent. MiR-195 family members can inhibit cancer cell proliferation, angiogenesis, epithelial-mesenchymal transition and metastases, immunosuppression, glycolysis, drug resistance, and cancer stem cell development by targeting the 3'-UTR of the mRNA of different pro-tumor genes. MiR-195 identified as a tumor suppressor miR in a variety of cancers, most notably gynecological malignancies such as cervical, endometrial, and ovarian carcinoma. As a result, restoring miR-195 expression should be regarded as a potential therapy for either prevention or treatment of gynecological cancers. This review will present the most recent data about miR-195-mediated anti-tumor effects in gynecological malignancies, emphasizing its downstream signaling pathways and target genes, as well as prospective treatment techniques.
不同类型的癌症已被证明下调 miR-195 的表达水平作为抗肿瘤药物。miR-195 家族成员可通过靶向不同促肿瘤基因的 mRNA 的 3'-UTR 抑制癌细胞增殖、血管生成、上皮间质转化和转移、免疫抑制、糖酵解、耐药性和癌症干细胞的发展。miR-195 在多种癌症中被鉴定为肿瘤抑制 miR，尤其是妇科恶性肿瘤，如宫颈癌、子宫内膜癌和卵巢癌。因此，恢复 miR-195 的表达应被视为预防或治疗妇科癌症的一种潜在疗法。本综述将介绍 miR-195 在妇科恶性肿瘤中介导的抗肿瘤作用的最新数据，强调其下游信号通路和靶基因，以及潜在的治疗技术。
